Cambrian Biopharma is the largest investor in cancer immunotherapy developer Sensei Biotherapeutics, which has filed to raise up to $100m.

Sensei Biotherapeutics, a US-based oncology treatment developer backed by medical research group Cambrian Biopharma, has filed for a $100m initial public offering on the Nasdaq Global Market. Founded in 1999, Sensei is developing immunotherapies to treat cancer and will put part of the IPO proceeds into an ongoing phase 1/2 clinical trial for its lead…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.